An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
Not yet recruiting · NCT07774611 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT07774611 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hangzhou Sumgen Biotech Co., Ltd. | 8 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | China | 33 |
| Dongguan People's Hospital | Dongguan | China | 12 |
| Fujian Cancer Hospital | Fuzhou | China | 55 |
| Harbin Medical University Cencer Hospital | Haerbin | China | 1 |
| Hunan Cancer Hospital | Changsha | China | 87 |
| Jilin Cancer Hospital | Changchun | China | 24 |
| Sun Yat-sen University Cancer Center | Guanzhou | China | 2 |
| The Affiliated Hospital of Chengde Medical University | Chengde | China | 2 |
| The First Affiliated Hospital of Henan Medical University | Xinxiang | China | 6 |
| The Second Xiangya Hospital of Central South University | Changsha | China | 39 |